Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
- Revenue in USD (TTM)82.92m
- Net income in USD1.76m
- Incorporated1999
- Employees180.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | 17.78m | -130.21m | 170.00m | 64.00 | -- | 1.18 | -- | 9.56 | -1.40 | -1.40 | 0.1973 | 1.33 | 0.0955 | -- | 57.07 | 277,781.30 | -69.97 | -48.16 | -78.78 | -55.11 | 14.87 | 40.47 | -732.42 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Liminatus Pharma Inc | 0.00 | -2.90m | 173.00m | -- | -- | -- | -- | -- | -0.4038 | -0.4038 | 0.00 | -2.24 | 0.00 | -- | -- | -- | -79.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -136.85 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -145.42m | 174.17m | 112.00 | -- | 0.7775 | -- | -- | -3.37 | -3.37 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -44.70 | -- | -48.84 | -- | -- | -- | -- | -- | -- | -- | 0.0026 | -- | -- | -- | -111.17 | -- | -- | -- |
| Crescent Biopharma Inc | 0.00 | -29.49m | 180.05m | 4.00 | -- | 2.48 | -- | -- | -45.72 | -45.72 | 0.00 | 5.23 | 0.00 | -- | -- | 0.00 | -146.71 | -55.66 | -182.66 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -27.13m | 183.59m | 15.00 | -- | 6.03 | -- | -- | -0.3911 | -0.3911 | 0.00 | 0.3054 | 0.00 | -- | -- | 0.00 | -91.36 | -125.08 | -142.54 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| TriSalus Life Sciences Inc | 32.14m | -30.30m | 185.03m | 110.00 | -- | -- | -- | 5.76 | -1.05 | -1.05 | 1.19 | -1.06 | 1.38 | 1.31 | 6.61 | 292,190.90 | -116.96 | -- | -267.11 | -- | 85.60 | -- | -84.63 | -- | 1.78 | -8.14 | -- | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -20.16m | 186.24m | 13.00 | -- | 8.89 | -- | -- | -1.12 | -1.12 | 0.00 | 0.8866 | 0.00 | -- | -- | 0.00 | -80.87 | -- | -115.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.65 | -- | -- | -- |
| Genfit SA (ADR) | 82.92m | 1.76m | 189.20m | 180.00 | 86.16 | 2.26 | 49.88 | 2.28 | -0.0837 | -0.0837 | 1.50 | 1.62 | 0.4362 | 512.25 | 5.44 | 460,667.40 | 0.9265 | -7.73 | 1.42 | -9.79 | 97.11 | 95.68 | 2.12 | -37.15 | 1.23 | 1.45 | 0.473 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Voyager Therapeutics Inc | 66.96m | -84.69m | 193.12m | 172.00 | -- | 0.7066 | -- | 2.88 | -1.46 | -1.46 | 1.15 | 4.94 | 0.1628 | -- | 24.06 | 389,290.70 | -20.59 | -1.01 | -23.85 | -1.27 | -- | -- | -126.49 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Agenus Inc | 99.52m | -190.81m | 193.56m | 316.00 | -- | -- | -- | 1.94 | -8.64 | -8.64 | 4.42 | -12.87 | 0.4358 | -- | 239.82 | 314,949.40 | -85.47 | -58.29 | -- | -140.29 | 99.48 | 97.31 | -196.12 | -125.67 | -- | -1.13 | -- | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Ventyx Biosciences Inc | 0.00 | -123.99m | 194.98m | 81.00 | -- | 0.8418 | -- | -- | -1.75 | -1.75 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -42.35 | -50.81 | -44.39 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 23.00k | -176.44m | 198.27m | 227.00 | -- | 0.4221 | -- | 8,620.41 | -3.17 | -3.17 | 0.0004 | 10.14 | 0.00004 | -- | -- | 101.32 | -30.80 | -32.02 | -32.01 | -33.96 | -- | -- | -767,126.10 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Citius Oncology Inc | 0.00 | -36.29m | 201.78m | -- | -- | 5.66 | -- | -- | -0.5229 | -0.5229 | 0.00 | 0.4981 | 0.00 | -- | -- | -- | -51.71 | -- | -115.22 | -- | -- | -- | -- | -- | 0.0543 | -- | 0.0964 | -- | -- | -- | -66.56 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -19.05m | 204.80m | 31.00 | -- | 1.79 | -- | -- | -0.21 | -0.21 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -15.73 | -46.29 | -16.66 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| AC Immune SA | 35.53m | -65.40m | 204.84m | 133.00 | -- | 1.72 | -- | 5.76 | -0.6549 | -0.6549 | 0.3546 | 1.19 | 0.1496 | -- | 47.48 | 267,170.30 | -27.53 | -27.41 | -39.31 | -30.60 | -- | -- | -184.05 | -505.58 | -- | -129.20 | 0.0518 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
Data as of Jul 14 2025. Currency figures normalised to Genfit SA's reporting currency: US Dollar USD
0.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Mar 2025 | 131.48k | 0.26% |
| Morgan Stanley & Co. International Plcas of 31 Mar 2025 | 25.52k | 0.05% |
| Old Mission Capital LLCas of 31 Mar 2025 | 22.24k | 0.04% |
| Optiver US LLCas of 31 Mar 2025 | 13.16k | 0.03% |
| Citadel Securities LLCas of 31 Mar 2025 | 12.33k | 0.03% |
| UBS Securities LLCas of 31 Mar 2025 | 3.12k | 0.01% |
| RhumbLine Advisers LPas of 31 Mar 2025 | 678.00 | 0.00% |
| Osaic Fa, Inc. (Investment Management)as of 31 Dec 2024 | 250.00 | 0.00% |
| BofA Securities, Inc.as of 31 Mar 2025 | 17.00 | 0.00% |
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
